The Use Of Intranasal (IN) Ketamine For Pain Control In Patients With Sickle Cell Disease And Vaso-occlusive Episode (VOE) In The Pediatric Emergency Department

Locations

2 United States sites

Age

3 to 25 Years

Genotypes

SS, SC

Phase

Phase 3

Study type

Interventional

Gender

All

Interventions

Drug

Compensation

Unknown

About the study

This will be a descriptive cohort study of intranasal ketamine as the initial analgesic for
children with sickle cell disease who present to the pediatric emergency department with
vaso-occlusive crisis and are awaiting intravenous line placement.

participation requirements

– History of Hemoglobin SS or SC disease

– Age 3 years old to 25 years old presenting to the PED with vaso-occlusive with
moderate-severe pain determined at triage as pain score (FACES or numeric rating
scale) ≥ 5

– Parent or patient willing to provide consent/assent

– English speaking

participation restrictions

– Patient with concern for more severe complications including acute chest, splenic
sequestration, sepsis, stroke, non-VOC pain, asthma exacerbation

– Allergy to ketamine

– GCS<15 - Obstructive nasal anatomy as per parent history - History of a psychiatric disorder - Pregnant patients will be excluded. Female patients > 12 years old are routinely
tested for pregnancy in our PED. Patients found to be pregnant will not be enrolled in
study.

Locations

  • Bronx, New York, United States, Jacobi Medical Center, 10461 [Not yet recruiting]
  • Bronx, New York, United States, JACOBI, 10461 [Recruiting]